Related Experiment Videos
In vivo immunosuppression by targeting a novel protease receptor
M A Duchosal1, A L Rothermel, P J McConahey
1Division of Haematology, Department of Internal Medicine, Centre-Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Nature
|March 28, 1996
Summary
Targeting the factor Xa receptor, effector cell protease receptor-1 (EPR-1), with an antisense oligonucleotide or monoclonal antibody suppressed immune responses. This indicates a novel role for protease receptors in immune regulation and suggests EPR-1 as a therapeutic target.
Area of Science:
- Immunology
- Vascular Biology
- Protease Signaling
Background:
- Membrane receptors for blood proteases regulate crucial physiological processes including blood clotting and cell growth.
- The role of these protease receptors in initiating or modulating immune responses remains largely unexplored.
- Vascular injury involves protease cascades, but their link to immune response generation is unclear.
Purpose of the Study:
- To investigate the involvement of protease receptors in the immune response.
- To determine if targeting the factor Xa receptor, effector cell protease receptor-1 (EPR-1), impacts lymphocyte proliferation and immune function.
- To explore EPR-1 as a potential therapeutic target for immunosuppression.
Main Methods:
- Utilized antisense oligonucleotides and a monoclonal antibody (mAb 2E1) to target EPR-1.
- Assessed CD3/T-cell receptor-dependent lymphocyte proliferation.
- Measured cytokine production and interleukin-2 (IL-2) receptor expression.
- Administered mAb 2E1 to severe-combined-immunodeficient (SCID) mice with human peripheral blood leukocytes.
Main Results:
- Targeting EPR-1 with antisense oligonucleotide or mAb 2E1 inhibited lymphocyte proliferation.
- Immunosuppression was achieved by reducing cytokine production and down-modulating IL-2 receptor expression.
- In vivo administration of mAb 2E1 suppressed human immunoglobulin production and graft-versus-host disease in SCID mice.
- mAb 2E1 treatment protected xenochimaeric mice from Epstein-Barr virus-induced lymphoproliferative disease.
Conclusions:
- Protease receptors, specifically EPR-1, play a significant role in regulating immune responses.
- Targeting EPR-1 demonstrates immunosuppressive effects both in vitro and in vivo.
- EPR-1 represents a promising new therapeutic target for managing immune-related conditions and achieving immunosuppression in humans.